SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the levels of three HIV medications: atazanavir,
darunavir and cobicistat in the blood after drug intake has been stopped, in order to
understand how long these drugs persist in the blood. The study will specifically look at
blood levels of these three drugs after taking them every day for 10 days. Participants will
take Evotaz (atazanavir and cobicistat) on a first stage and Rezolsta (darunavir and
cobicistat) on a second stage.
If the participants decide to take part, the duration of the study will be up to 33 days plus
a screening visit which will take place up to 28 days prior to the start of the study, and a
follow up visit, which takes place 7 to 14 days after the last dose of study medication. This
study is not randomised which means that all participants will receive all study medications
in the same order.
The participant and the study doctor will know which study medications the participant is
taking at all times during the study.